France is the second-largest economy in the European Union and one of the largest consumers of pharmaceutical products in the world. Unique to France’s market, regulators look beyond a drug’s clinical trial endpoints and consider if the drug represents an improvement in medical services and cost compared to existing drugs.
From a communications and marketing perspective, the health regulations in the country are changing to avoid repeating major health crises. Consequently, the National Agency for the Safety of Medicines and Health Products (ANSM) has in recent years created stricter legal constraints regarding publicity within the healthcare industry.
Sign up to get the guides
Select the guides you wish to download